Close Menu

NEW YORK – Foundation Medicine said on Wednesday that it has signed a non-exclusive licensing agreement with TwinStrand Biosciences for a sequencing-based technology for rare mutation detection.

The agreement covers two foundational patent families from TwinStrand, a University of Washington spinout based in Seattle. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.